mti 7164 actigraph accelerometers (ActiGraph llc)
90
Structured Review
ActiGraph llc
mti 7164 actigraph accelerometers
Mti 7164 Actigraph Accelerometers, supplied by ActiGraph llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mti+7164/mti+7164/pmc11933046-11-37-39
Average 90 stars, based on 1 article reviews
Mti 7164 Actigraph Accelerometers, supplied by ActiGraph llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mti+7164/mti+7164/pmc11933046-11-37-39
Average 90 stars, based on 1 article reviews
mti 7164 actigraph accelerometers - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Associations between objectively measured habitual physical activity and adiposity in children and adolescents: Systematic review. Article Snippet: This review examined recent evidence on associations between objectively measured habitual physical activity and adiposity.. A search for observational studies was carried out using several electronic databases from June 2004 June 2008.. Of 1 255 potentially eligible papers, 47 papers were included, which described 48 studies. Article Title: Epigenome-wide association study of objectively measured physical activity in peripheral blood leukocytes. Article Snippet: Objectively measured physical activity was measured with either the Article Title: Associations of Objectively Measured Vigorous Physical Activity With Body Composition, Cardiorespiratory Fitness, and Cardiometabolic Health in Youth: A Review Article Snippet: The Actigraph GT1M model was primarily used (33.3%; n = 15) §§ or one of its predecessors (ActiGraph 7164, MTI 7164, or CSA 7164; 43.9%; n = 18), ‖‖ but even when using the same model, VPA cutpoints applied were inconsistent (eg, Article Title: Device-measured sedentary behaviour and anxiety symptoms during adolescence: a 6-year prospective cohort study Article Snippet: Activity data were collected at ages 11.8, 13.9, and 15.5 (which we refer to as ages 12, 14, and 16) using Western Blot:Article Title: A comparison of the associations between bone health and three different intensities of accelerometer-derived habitual physical activity in children and adolescents: a systematic review Article Snippet: Szmodis et al. 2019 [ ] Cross-sectional ◆ , n = 123 (64/59) m, 11.12 ± 0.68 years f, 10.96 ± 0.75 years All girls pre-menarcheal , Actigraph GT3X + 5-s epoch Location: NR Worn for: 5 days (1 WE) 24 h/day, except WB activities For inclusion: 5 days with measured daily activity from 6 am to 8 pm (1WE) Non-wear: NR , MPA, 500–3999 cpm MVPA, > 500 cpm VPA, 4000–7599 cpm VVPA, > 7600 cpm (min/day): MPA : m, 138.07 ± 30.63 f, 117.7 ± 38.79* ALL, 128.36 ± 37.48 MVPA : m, 159.23 ± 36.90; f, 133.44 ± 44.28* ALL, 147.37 ± 44.13 VPA : m, 22.13 ± 12.13; f, 16.27 ± 8.24* ALL, 19.43 ± 10.19 VVPA : m, 3.13 ± 2.22 f, 4.21 ± 4.07 ALL, 3.63 ± 3.27 , QUS (SONOST3000, Seoul, Korea) Calcanues SOS (m/s), BUA (dBMHz), BQI , Pearson’s correlation analysed the relationship between bone and PA parameters (MPA, MVPA, VPA, VVPA) SOS: Whole sample: MPA : r = 0.05, p > 0.05; MVPA : r = 0.09, p > 0.05; VPA : r = 0.23, p < 0.05; VVPA : − 0.09, p > 0.05 Boys: MPA : r = 0.09, p > 0.05; MVPA : r = 0.23, p > 0.05; VPA : r = 0.46, p < 0.001; VVPA : 0.21, p > 0.05 Girls: MPA : r = − 0.10, p > 0.05; MVPA : r = − 0.12, p > 0.05; VPA : r = − 0.10, p > 0.05; VVPA : − 0.17, p > 0.05 BUA: Whole sample: MPA : r = 0.08, p > 0.05; MVPA : r = 0.12, p > 0.05; VPA : r = 0.25, p < 0.05; VVPA : − 0.03, p > 0.05 Boys: MPA : r = 0.15, p > 0.05; MVPA : r = 0.15, p > 0.05; VPA : r = 0.33, p < 0.01; VVPA : 0.14, p > 0.05 Girls: MPA : r = − 0.02, p > 0.05; MVPA : r = − 0.01, p > 0.05; VPA : r = 0.00, p > 0.05; VVPA : − 0.10, p > 0.05 BQI: Whole sample: MPA : r = 0.12, p > 0.05; MVPA : r = 0.15, p > 0.05; VPA : r = 0.29, p < 0.01; VVPA : − 0.06, p > 0.05 Boys: MPA : r = 0.12, p > 0.05; MVPA : r = 0.25, p > 0.05; VPA : r = 0.47, p < 0.001; VVPA : 0.23, p > 0.05 Girls: MPA : r = − 0.06, p > 0.05; MVPA : r = − 0.07, p > 0.05; VPA : r = − 0.08, p > 0.05; VVPA : − 0.16, p > 0.05. .. Sayers et al. 2011 [ ] Cross-sectional ◆◆ , n = 1748 (778/970) 15.4 ± 0.23 years ALSPAC Tanner stages 1–2/3/4–5 (%): m, 2/12/86 f, 1/8/91 , MTI 7164 or Actigraph GT1M 60-s epoch Location: right hip Worn for: 7 days during waking hours (except WB activity) For inclusion: ≥ 3 days with ≥ 10 h Non-wear: NR , MPA, 3600–6199 cpm VPA, > 6200 cpm (min/day) MPA : m, 25.6 ± 17.1; f, 15.8 ± 13.2 VPA : m, 4.3 ± 5.8 f, 2.2 ± 3.7 , pQCT (Stratec XCT2000L) Mid (50%) right tibia BMCc (mg), BMDc (mg/cm 3 ), BAc (mm 2 ), PC (mm), EC (mm) , Linear regression was used to examine associations between MPA and VPA and pQCT bone outcomes (adjusted for age and height at time of pQCT measurement and duration of accelerometer recording) β coefficient represents SD change in pQCT parameter per doubling in MPA or VPA Cortical BMC: Boys: MPA : β ( 95% CI ) = 0.011 (− 0.033, 0.054), p = 0.6303; VPA : β ( 95% CI ) = 0.041 (0.004, 0.077), p = 0.0280 Girls: MPA : β ( 95% CI ) = 0.033 (− 0.002, 0.068), p = 0.0656; VPA : β ( 95% CI ) = 0.070 (0.031, 0.109), p = 0.0004 All: MPA : β ( 95% CI ) = 0.024 (− 0.003, 0.051), p = 0.0835; VPA : β ( 95% CI ) = 0.055 (0.028, 0.081), p = 0.00001 Cortical BA: Boys: MPA : β ( 95% CI ) = 0.022 (− 0.019, 0.062), p = 0.2959; VPA : β ( 95% CI ) = 0.050 (0.016, 0.085), p = 0.0039 Girls: MPA : β ( 95% CI ) = 0.032 (− 0.001, 0.065), p = 0.0611; VPA : β ( 95% CI ) = 0.068 (0.032, 0.105), p = 0.0002 All: MPA : β ( 95% CI ) = 0.028 (0.002, 0.053), p = 0.0347; VPA : β ( 95% CI ) = 0.059 (0.034, 0.084), p = 0.0000 Cortical BMD: Boys: MPA : β ( 95% CI ) = − 0.055 (− 0.095, − 0.015), p = 0.0074; VPA : β ( 95% CI ) = − 0.048 (− 0.082, − 0.014), p = 0.0062 Girls: MPA : β ( 95% CI ) = − 0.004 (− 0.037, 0.028), p = 0.7893; VPA : β ( 95% CI ) = − 0.012 (− 0.048, 0.024), p = 0.5206 All: MPA : β ( 95% CI ) = − 0.025 (− 0.050, 0.001), p = 0.0574; VPA : β ( 95% CI ) = − 0.031 (− 0.056, − 0.006), p = 0.0150 Periosteal circumference: Boys: MPA : β ( 95% CI ) = − 0.009 (− 0.050, 0.031), p = 0.6486; VPA : β ( 95% CI ) = 0.020 (− 0.015, 0.054), p = 0.2671 Girls: MPA : β ( 95% CI ) = 0.032 (− 0.001, 0.065), p = 0.0606; VPA : β ( 95% CI ) = 0.057 (0.021, 0.094), p = 0.0022 All: MPA : β ( 95% CI ) = 0.015 (− 0.010, 0.041), p = 0.2439; VPA: β ( 95% CI ) = 0.037 (0.012, 0.063), p = 0.0037 Endosteal circumference (adjusted periosteal circumference): Boys: MPA : β ( 95% CI ) = − 0.029 (− 0.064, 0.005), p = 0.0946; VPA : β ( 95% CI ) = − 0.044 (− 0.073, − 0.015), p = 0.0033 Girls: MPA : β ( 95% CI ) = − 0.012 (− 0.041, 0.016), p = 0.3901; VPA : β ( 95% CI ) = − 0.038 (− 0.069, − 0.007), p = 0.0167 All: MPA : β ( 95% CI ) = − 0.019 (− 0.041, 0.003), p = 0.0848; VPA : β ( 95% CI ) = − 0.041 (− 0.062, − 0.020), p = 0.00002. .. Specker et al., 2001 † [ ] Cross-sectional ◆ , n = 239 (124/115) m, 4.0 ± 0.6 years f, 3.9 ± 0.6 years NR , Actiwatch motion sensor Epoch NR (PA described in cpm in methods, 60 s assumed) Location: lumbar spine Worn for: 2 days For inclusion: 2 days Non-wear: NR , MVPA: > 500 cpm VPA: > 1000 cpm Average % time: MVPA : m, 13.5 ± 3.9; f, 12.1 ± 4.2* VPA : m, 5.2 ± 2.2; f, 4.5 ± 2.2* , pQCT (Norland/Stratec XCT2000) 20% distal tibia BAc (mm 2 ), PC (mm), EC (mm) , Forward–backward stepwise regression was performed including variables that were significant ( p ≤ 0.05). After obtaining final models, PA measures were added to assess whether they explained a significant amount of remaining error Periosteal circumference: MVPA : NS; VPA : NS Endosteal circumference: MVPA : NS; VPA : NS Cortical BA: MVPA : NS; VPA : NS. Activity Assay:Article Title: A comparison of the associations between bone health and three different intensities of accelerometer-derived habitual physical activity in children and adolescents: a systematic review Article Snippet: Szmodis et al. 2019 [ ] Cross-sectional ◆ , n = 123 (64/59) m, 11.12 ± 0.68 years f, 10.96 ± 0.75 years All girls pre-menarcheal , Actigraph GT3X + 5-s epoch Location: NR Worn for: 5 days (1 WE) 24 h/day, except WB activities For inclusion: 5 days with measured daily activity from 6 am to 8 pm (1WE) Non-wear: NR , MPA, 500–3999 cpm MVPA, > 500 cpm VPA, 4000–7599 cpm VVPA, > 7600 cpm (min/day): MPA : m, 138.07 ± 30.63 f, 117.7 ± 38.79* ALL, 128.36 ± 37.48 MVPA : m, 159.23 ± 36.90; f, 133.44 ± 44.28* ALL, 147.37 ± 44.13 VPA : m, 22.13 ± 12.13; f, 16.27 ± 8.24* ALL, 19.43 ± 10.19 VVPA : m, 3.13 ± 2.22 f, 4.21 ± 4.07 ALL, 3.63 ± 3.27 , QUS (SONOST3000, Seoul, Korea) Calcanues SOS (m/s), BUA (dBMHz), BQI , Pearson’s correlation analysed the relationship between bone and PA parameters (MPA, MVPA, VPA, VVPA) SOS: Whole sample: MPA : r = 0.05, p > 0.05; MVPA : r = 0.09, p > 0.05; VPA : r = 0.23, p < 0.05; VVPA : − 0.09, p > 0.05 Boys: MPA : r = 0.09, p > 0.05; MVPA : r = 0.23, p > 0.05; VPA : r = 0.46, p < 0.001; VVPA : 0.21, p > 0.05 Girls: MPA : r = − 0.10, p > 0.05; MVPA : r = − 0.12, p > 0.05; VPA : r = − 0.10, p > 0.05; VVPA : − 0.17, p > 0.05 BUA: Whole sample: MPA : r = 0.08, p > 0.05; MVPA : r = 0.12, p > 0.05; VPA : r = 0.25, p < 0.05; VVPA : − 0.03, p > 0.05 Boys: MPA : r = 0.15, p > 0.05; MVPA : r = 0.15, p > 0.05; VPA : r = 0.33, p < 0.01; VVPA : 0.14, p > 0.05 Girls: MPA : r = − 0.02, p > 0.05; MVPA : r = − 0.01, p > 0.05; VPA : r = 0.00, p > 0.05; VVPA : − 0.10, p > 0.05 BQI: Whole sample: MPA : r = 0.12, p > 0.05; MVPA : r = 0.15, p > 0.05; VPA : r = 0.29, p < 0.01; VVPA : − 0.06, p > 0.05 Boys: MPA : r = 0.12, p > 0.05; MVPA : r = 0.25, p > 0.05; VPA : r = 0.47, p < 0.001; VVPA : 0.23, p > 0.05 Girls: MPA : r = − 0.06, p > 0.05; MVPA : r = − 0.07, p > 0.05; VPA : r = − 0.08, p > 0.05; VVPA : − 0.16, p > 0.05. .. Sayers et al. 2011 [ ] Cross-sectional ◆◆ , n = 1748 (778/970) 15.4 ± 0.23 years ALSPAC Tanner stages 1–2/3/4–5 (%): m, 2/12/86 f, 1/8/91 , |
